These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 17414592

  • 1. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
    Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
    [Abstract] [Full Text] [Related]

  • 2. Oat-derived beta-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia.
    Reyna-Villasmil N, Bermúdez-Pirela V, Mengual-Moreno E, Arias N, Cano-Ponce C, Leal-Gonzalez E, Souki A, Inglett GE, Israili ZH, Hernández-Hernández R, Valasco M, Arraiz N.
    Am J Ther; 2007; 14(2):203-12. PubMed ID: 17414591
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
    Cattin L, Da Col PG, Feruglio FS, Finazzo L, Rimondi S, Descovich G, Manzato E, Zambon S, Crepaldi G, Siepi D.
    Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM, Vega GL, Tomassini JE, Tershakovec AM.
    Am J Cardiol; 2009 Aug 15; 104(4):548-53. PubMed ID: 19660610
    [Abstract] [Full Text] [Related]

  • 6. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 15; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 7. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR.
    Am J Cardiol; 2008 Aug 15; 102(4):429-33. PubMed ID: 18678300
    [Abstract] [Full Text] [Related]

  • 8. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
    Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF.
    Int Angiol; 1998 Dec 15; 17(4):225-33. PubMed ID: 10204653
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Effectiveness of ciprofibrate. Open study in a Portuguese population].
    Silva JM, Branco MC, Pereira M, Figueiredo H, Jesus LC, de Moura JP, Ferreira MR, Serra e Silva P.
    Rev Port Cardiol; 1995 Apr 15; 14(4):313-22, 284. PubMed ID: 7612280
    [Abstract] [Full Text] [Related]

  • 12. Niacin-based therapy for dyslipidemia: past evidence and future advances.
    Ito MK.
    Am J Manag Care; 2002 Sep 15; 8(12 Suppl):S315-22. PubMed ID: 12240703
    [Abstract] [Full Text] [Related]

  • 13. Significance of alterations in plasma lipid profile levels in breast cancer.
    Franky Dhaval Shah, Shilin Nandubhai Shukla, Pankaj Manubhai Shah, Patel HR, Prabhudas Shankerbhai Patel.
    Integr Cancer Ther; 2008 Mar 15; 7(1):33-41. PubMed ID: 18292593
    [Abstract] [Full Text] [Related]

  • 14. Does obesity influence ciprofibrate activity?
    Silva JM, Serra e Silva P.
    Rev Port Cardiol; 1998 Apr 15; 17(4):329-34. PubMed ID: 9632956
    [Abstract] [Full Text] [Related]

  • 15. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.
    Metabolism; 2001 Jun 15; 50(6):729-33. PubMed ID: 11398153
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES.
    J Am Coll Cardiol; 2005 Jan 18; 45(2):185-97. PubMed ID: 15653014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.